Dr. Eli D. Kirshner

Claim this profile

The Valley Hospital - Luckow Pavilion

Studies Prostate Adenocarcinoma
Studies Lung Cancer
6 reported clinical trials
27 drugs studied

Area of expertise

1

Prostate Adenocarcinoma

Eli D. Kirshner has run 3 trials for Prostate Adenocarcinoma. Some of their research focus areas include:

Stage IV
2

Lung Cancer

Eli D. Kirshner has run 2 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage III

Affiliated Hospitals

Image of trial facility.

The Valley Hospital-Luckow Pavilion

Image of trial facility.

Valley Health System Ridgewood Campus

Clinical Trials Eli D. Kirshner is currently running

Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting

2 awards

Phase 3

31 criteria

Image of trial facility.

Relugolix + Radiation

for Advanced-Stage Prostate Cancer

This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body (oligometastatic). Relugolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. It may stop the growth of cancer cells that need testosterone to grow. Radiation therapy uses high-energy x rays or protons to kill tumor cells. The addition of relugolix to the radiation may reduce the chance of oligometastatic prostate cancer spreading further.

Recruiting

0 awards

Phase 2

More about Eli D. Kirshner

Clinical Trial Related

5 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Eli D. Kirshner has experience with

  • Pembrolizumab
  • Relugolix
  • Bicalutamide
  • Buserelin
  • Degarelix
  • Flutamide

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Eli D. Kirshner specialize in?

Is Eli D. Kirshner currently recruiting for clinical trials?

Are there any treatments that Eli D. Kirshner has studied deeply?

What is the best way to schedule an appointment with Eli D. Kirshner?

What is the office address of Eli D. Kirshner?

Is there any support for travel costs?